Contract awarded for products that bring improvement to
healthcare industry
LONDON, May 2, 2023
/PRNewswire/ -- Smith+Nephew (LSE: SN, NYSE: SNN), the global
medical technology company, today announces its PICO Single Use
Negative Pressure Wound Therapy Systems have received an Innovative
Technology contract from Vizient, Inc. the nation's largest
member-driven health care performance improvement company. The
contract was awarded based on the recommendation of the PICO Single
Use Negative Pressure Wound Therapy Systems by hospital experts who
serve on one of Vizient's member-led councils, and it signifies to
Vizient members unique qualities that potentially bring improvement
to the healthcare industry.
Innovative Technology contracts are recommended after review and
interaction with products submitted through Vizient's Innovative
Technology Program. Vizient member-led councils identify
technologies that have the potential to enhance clinical care,
patient safety, health care worker safety or improve business
operations of health care organizations.
The PICO sNPWT System provides a portable, easy to use,
canister-free design and is equipped with the comfort and mobility
of Smith+Nephew soft port technology. This proprietary,
silicone-based, four-layer technology uniquely manages wound fluid
by simultaneously evaporating and locking it away, keeping excess
moisture away from the wound and periwound
area.1
This technology also offers expansion of NPWT benefits beyond the
wound site by providing compression to the periwound area, which
may help improve perfusion.2
The PICO System received this award after being cleared by the
Food and Drug Administration (FDA) as the first sNPWT system
indicated to aid in reducing the incidence of superficial and deep
incisional surgical site infections (SSIs) for high-risk patients
in Class I and Class II wounds, post-operative Seroma, and
Dehiscence.
"We are thrilled that our PICO System has been recognized by
healthcare experts in receiving this distinguished Innovative
Technology contract in the US. Surgical site complications continue
to be costly events that plague our patients and healthcare
systems. "Our PICO technology has been shown to reduce the risk of
SSIs across multiple specialties, improving patient care and
helping get them home sooner" said Laura
Ackerman, Vice President and General Manager, NPWT at
Smith+Nephew. "We are committed to innovating the standard of care
for patients, and this recognition of the PICO System by Vizient
further validates that commitment."
References
- Malmsjö, M., Huddleston, E., & Martin, R. (2014).
Biological effects of a disposable, canisterless Negative Pressure
Wound Therapy system (in-vitro). Eplasty, 14: e15.
- Sugrue, Michael et al. 2016. "World Union of Wound Healing
Societies (WUWHS) Consensus Document. Closed Surgical Incision
Management: Understanding the Role of NPWT." Wounds
International.
About Vizient
Vizient represents a diverse membership
that includes academic medical centers, pediatric facilities,
community hospitals, integrated health delivery networks and
non-acute healthcare providers and represents approximately
$130 billion in annual purchasing
volume. Through its Innovative Technology Program, Vizient works
with member-led councils and task forces to evaluate products for
their potential to bring real innovation to healthcare. Vizient may
award a contract to products deemed worthy of the Innovative
Technology designation outside of the competitive bid cycle.
About Smith+Nephew
Smith+Nephew is a portfolio medical
technology company focused on the repair, regeneration and
replacement of soft and hard tissue. We exist to restore people's
bodies and their self-belief by using technology to take the limits
off living. We call this purpose 'Life Unlimited'. Our 19,000
employees deliver this mission every day, making a difference to
patients' lives through the excellence of our product
portfolio, and the invention and application of new technologies
across our three global franchises of Orthopaedics, Sports
Medicine & ENT and Advanced Wound Management.
Founded in Hull, UK, in 1856,
we now operate in more than 100 countries, and generated annual
sales of $5.2 billion in 2022.
Smith+Nephew is a constituent of the FTSE100 (LSE: SN, NYSE: SNN).
The terms 'Group' and 'Smith+Nephew' are used to refer to Smith
& Nephew plc and its consolidated subsidiaries, unless the
context requires otherwise.
For more information about Smith+Nephew, please
visit www.smith-nephew.com and follow us
on Twitter, LinkedIn, Instagram or Facebook.
Forward-looking Statements
This document may
contain forward-looking statements that may or may not prove
accurate. For example, statements regarding expected revenue growth
and trading margins, market trends and our product pipeline are
forward-looking statements. Phrases such as "aim", "plan",
"intend", "anticipate", "well-placed", "believe", "estimate",
"expect", "target", "consider" and similar expressions are
generally intended to identify forward-looking statements.
Forward-looking statements involve known and unknown risks,
uncertainties and other important factors that could cause actual
results to differ materially from what is expressed or implied by
the statements. For Smith+Nephew, these factors include: risks
related to the impact of Covid, such as the depth and longevity of
its impact, government actions and other restrictive measures taken
in response, material delays and cancellations of elective
procedures, reduced procedure capacity at medical facilities,
restricted access for sales representatives to medical facilities,
or our ability to execute business continuity plans as a result of
Covid; economic and financial conditions in the markets we serve,
especially those affecting healthcare providers, payers and
customers (including, without limitation, as a result of Covid);
price levels for established and innovative medical devices;
developments in medical technology; regulatory approvals,
reimbursement decisions or other government actions; product
defects or recalls or other problems with quality management
systems or failure to comply with related regulations; litigation
relating to patent or other claims; legal and financial compliance
risks and related investigative, remedial or enforcement actions;
disruption to our supply chain or operations or those of our
suppliers (including, without limitation, as a result of Covid);
competition for qualified personnel; strategic actions, including
acquisitions and dispositions, our success in performing due
diligence, valuing and integrating acquired businesses; disruption
that may result from transactions or other changes we make in our
business plans or organisation to adapt to market developments;
relationships with healthcare professionals; reliance on
information technology and cybersecurity; disruptions due to
natural disasters, weather and climate change related events;
changes in customer and other stakeholder sustainability
expectations; changes in taxation regulations; effects of foreign
exchange volatility; and numerous other matters that affect us or
our markets, including those of a political, economic, business,
competitive or reputational nature. Please refer to the documents
that Smith+Nephew has filed with the U.S. Securities and Exchange
Commission under the U.S. Securities Exchange Act of 1934, as
amended, including Smith+Nephew's most recent annual report on Form
20-F, which is available on the SEC's website at www.
sec.gov, for a discussion of certain of these factors. Any
forward-looking statement is based on information available to
Smith+Nephew as of the date of the statement. All written or oral
forward-looking statements attributable to Smith+Nephew are
qualified by this caution. Smith+Nephew does not undertake any
obligation to update or revise any forward-looking statement to
reflect any change in circumstances or in Smith+Nephew's
expectations.
™ Trademark of Smith+Nephew. Certain marks registered in US
Patent and Trademark Office.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/smithnephew-receives-innovative-technology-contract-from-vizient-for-pico-single-use-negative-pressure-wound-therapy-systems-301812808.html
SOURCE Smith & Nephew plc